patent.fyi
Applications  /  US 2026/0356939
United States Patent Application Publication

US 2026/0356939 A1

Published
Nov 12, 2026
Filed
Oct 25, 2023
Earliest date on the face
Oct 25, 2022
Classification
C07K 16/2803
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Masking an activating ligand

What ifWhat if a binding fragment reduced NK cell activation by masking MICA on graft cells?
Claim language“binding to human inhibitory KIR”

An Fc-free antibody fragment covers the NKG2D-binding surface of MICA on graft cells. Blocking this interaction reduces the activating signal that contributes to NK cell degranulation.

1.1Sequestration of extracellular IL-15

What ifWhat if a soluble binding protein reduced NK cell priming by capturing extracellular IL-15?
Claim language“binding to human inhibitory KIR”

A soluble IL-15-binding protein sequesters free IL-15 before it associates with IL-15 receptor alpha on accessory cells. Reduced cytokine presentation limits IL-15-dependent priming of NK cell cytotoxicity.

1.1Physical separation from NK cells

What ifWhat if a porous capsule protected graft cells by separating them from NK cells?
Claim language“inhibiting an NK cell”

A semipermeable hydrogel capsule encloses the graft cells and excludes intact NK cells. Oxygen, nutrients and small metabolic products diffuse through the capsule wall while the wall blocks direct cell contact.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference control for diagnostic assay development

A diagnostic assay development laboratory uses an inhibitory KIR agonist as a reference reagent in an NK cell cytotoxicity assay. Paired wells contain fluorescently labeled target cells and NK cells that express the corresponding inhibitory KIR. One well contains the agonist and the other contains a matched carrier control. The difference in target cell death measures the assay's response to receptor-mediated inhibition.

Component substitution

Native ligand replaces antibody binding domain

A peptide-loaded HLA-C molecule from the C2 group replaces the antibody-derived binding domain in a reagent directed at inhibitory KIR2DL1. The HLA-C ectodomain is assembled with beta-2 microglobulin and a peptide that supports KIR2DL1 binding. A membrane-proximal tether anchors the complex to a supported lipid bilayer alongside an activating ligand. Contact with the bilayer brings inhibitory and activating receptors into the same interface, where KIR2DL1 engagement reduces NK cell degranulation.

Magnetic beads replace the display cell

Superparamagnetic beads replace living cells as the surface that displays an inhibitory KIR agonist. The bead coating immobilizes the agonist and a defined activating ligand so that each bead presents both signals to a contacting NK cell. Paired control beads carry the same activating ligand and a receptor-inert surface filler. A magnet removes the beads before flow cytometry measures NK cell surface CD107a.

Parameter or scale variation

Surface density series for receptor inhibition

Target cell mimics present the same inhibitory KIR agonist at nominal densities of 10, 100, and 1,000 molecules per square micrometer. Each surface carries the same density of activating ligand, and an agonist-free surface provides a baseline. Fluorescence calibration measures the actual agonist density on each surface. NK cell surface CD107a measured after 60 minutes provides a degranulation readout for the density series.

Combination with existing systems

Agonist testing in a perfused organoid chip

A perfused organoid chip holds a human tissue organoid beside a microfluidic channel that carries primary human NK cells. The organoid surface presents a membrane-tethered inhibitory KIR agonist, and the perfusate contains NK cells that express the matching receptor. Time-lapse fluorescence imaging records NK cell contact and tissue cell death. A parallel channel with matched organoids lacking the surface agonist provides a baseline under the same flow conditions.

Automated or data-driven variant

Automated imaging of NK cell inhibition

A liquid-handling robot dispenses agonist concentrations, fluorescently labeled target cells, and receptor-matched NK cells into a multiwell plate. An automated microscope records target cell fluorescence and uptake of a membrane-impermeant death dye at fixed intervals. Image analysis counts dead target cells over time and corrects for spontaneous death using target-only wells. Software fits the concentration-response curve and reports the half-maximal inhibitory concentration with a confidence interval.

Specific version of a part

HLA-C1 display for KIR2DL3

The graft cell surface displays peptide-loaded HLA-C with asparagine at residue 80, the defining residue of the C1 group. A peptide–HLA-C complex that binds KIR2DL3 recruits inhibitory signaling in NK cells that express the receptor.

Surface-anchored agonist antibody fragment

A graft cell displays a single-chain antibody fragment on its membrane through a transmembrane anchor. The fragment binds an extracellular site on KIR2DL1 and clusters the receptor at the cell contact, where its intracellular inhibitory motifs recruit phosphatases that reduce NK cell activation.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0216069 A1
Published
Aug 2, 2018
Filed
Jan 22, 2018
Class
C12N 5/0646
Document BUS 2021/0355446 A1
Published
Nov 18, 2021
Filed
Nov 22, 2019
Class
C12N 5/0646
Document CUS 2021/0077527 A1
Published
Mar 18, 2021
Filed
Sep 11, 2020
Class
A61K 35/17
Claim 1
Document A
Document B
1.1A substance having activity of binding to human inhibitory KIR and inhibiting an NK cell.
In a preferred embodiment, the invention provides an antibody that binds both KIR2DL1 and KIR2DL2/3 human receptors, reverses inhibition of NK cell cytotoxicity mediated by these KIRs, and competes with DF200, 1-7F9, or NKVSF1 for binding to the KIR2DL1 human receptor, the KIR2DL2/3 human receptor, or both KIR2DL1 and KIR2DL2/3 human receptors.
A · US 2018/0216069 A1 · ¶ 23
Tolerance of NK cells for self is mainly achieved by inhibitory killer cell immunoglobulin-like receptors (KIRs) and CD94/NKG2A-receptors on NK cells for HLA class I molecules on somatic cells [3]. Interactions of those inhibitory receptors with HLA class I molecules on autologous normal cells induce dominant negative signals which override activating signals and therefore prevent cytotoxic activity as defined by the “missing-self” hypothesis [5, 6].
B · US 2021/0355446 A1 · ¶ 2

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to antibodies, antibody fragments, and derivatives thereof that cross-react with two or more inhibitory receptors present on the cell surface of NK cells and potentiate NK cell cytotoxicity in mammalian subjects or in a biological sample.
A · US 2018/0216069 A1 · ¶ 2
Accordingly, effective NK cell-mediated therapy may require both a stimulation of these cells and a neutralization of inhibitory signals.
A · US 2018/0216069 A1 · ¶ 6
The invention can be used as an “off the shelf” artificial feeder cell that can be readily designed to expand a NK cell or a NK subset of interest and also specifically expand NK cells modified with a chimeric antigen receptor (CAR).
B · US 2021/0355446 A1 · ¶ 1
By genetically introducing or knockdown of candidate genes, the artificial feeder cell of the invention can be used to identify the stimulatory, co-stimulatory, and any other factors that mediate growth, expansion and cytotoxicity of a NK cell.
B · US 2021/0355446 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0356939 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356939/, SHA-256 7befebf52f1757634862afbd0e69b3d1a8b894200a9e8da5e44e9b6bf083e2c8
First published
Permanent addresshttps://patent.fyi/US20260356939/
Content fingerprint (SHA-256)7befebf52f1757634862afbd0e69b3d1a8b894200a9e8da5e44e9b6bf083e2c8
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi